SLC7A11 and cancer: However, the addition of dyclonine regained the cytotoxic action of each of these agents in OSC19-SSZR cells (Figure 3A), suggesting that dyclonine is indeed able to abolish the acquired resistance to xCT- or GSH-targeted therapy in cancer cells.